i3 Statprobe Selected to Assume Bulk of Eli Lilly and Company's U.S. Data Management Work

ANN ARBOR, Mich.--(BUSINESS WIRE)--Pharmaceutical services company i3 announced today that global pharmaceutical firm Eli Lilly and Company (NYSE: LLY) is transferring the majority of its U.S. data management work to i3 Statprobe, a leader in clinical data services, as part of Lilly’s ongoing effort to transform its business. This significantly expands the business relationship between the two organizations.